CDKN1C and cancer: After OTX015 SCLC resistant and sensitive cells differed presenting an up-regulation of CDKN2D (P19) in resistant cells, and of CDKN1C (P57) in the sensitive cells, changes that could be linked with the different sensitivity to anti-cancer drugs [49, 50].